What PBM Contracts Don’t Explain (and Why It Matters to Employers)

PBM contracts are often treated as definitive documents. Once signed, employers assume the terms clearly define how prescription benefits will be managed, how costs will flow, and how accountability will be enforced. 

In reality, PBM contracts often explain how things are priced without fully explaining how decisions are made. 

That gap matters. Especially as pharmacy spend continues to rise and scrutiny around oversight increases. 

Why PBM Contracts Feel Complete but Aren’t 

Most PBM contracts are dense, technical, and heavily negotiated. They outline benchmarks, guarantees, and fees in precise language. 

What they rarely do is explain: 

• Where incentives exist beyond the contract language 
• How discretionary decisions affect cost 
• Which revenue streams sit outside standard definitions 
• What happens when market dynamics change mid-contract 

The contract may be accurate, but it is rarely comprehensive.   

What PBM Contracts Typically Define Well  

To be fair, PBM contracts are effective at documenting certain elements.

They usually spell out:

• Pricing benchmarks for drugs and dispensing fees
• Administrative and clinical program fees
• Rebate guarantees or minimums
• Term lengths and renewal provisions 

These components are measurable and auditable. They give employers a sense of structure and predictability. 

But structure alone does not equal transparency. 

What PBM Contracts Often Leave Unclear

The most important cost drivers in pharmacy are frequently shaped by areas that contracts reference indirectly or not at all.

Incentives Behind Formulary Decisions

Contracts may describe formulary categories, but they rarely explain why certain drugs are preferred. Rebate arrangements, manufacturer relationships, and volume commitments can all influence placement without being fully visible to the employer.

Specialty Pharmacy Economics

Specialty drugs are often governed by separate agreements, networks, or carve-outs. Contracts may permit exclusive arrangements without clarifying how pricing, sourcing, or margins are determined.

For employers, this creates exposure in one of the highest-cost areas of the plan.

Revenue Streams Outside Core Definitions

Administrative fees and ingredient costs are defined, but other revenue streams such as data access fees, manufacturer service payments, and program fees may exist outside standard pass-through language.

If it is not explicitly defined, it is often overlooked.

Decision-Making Authority

PBM contracts frequently grant broad discretion to make operational decisions. That flexibility benefits efficiency, but it also means employers may have limited visibility into choices that directly affect spend.

Why This Matters More Now

As employers face rising prescription costs, the expectation is shifting from acceptance to oversight.

CFOs and HR leaders are increasingly expected to:

• Understand where plan dollars are going
• Demonstrate that vendors are monitored, not just contracted
• Explain benefit decisions to leadership and, in some cases, boards

When PBM contracts leave critical dynamics unexplained, employers are exposed to questions they may not be prepared to answer.

The Broker’s Role as Interpreter

This is where brokers and advisors add significant value.

Rather than acting as contract reviewers alone, effective brokers help clients understand:

• What the contract governs versus what it allows
• Where assumptions may be driving outcomes
• Which areas require ongoing oversight beyond renewal

By translating contract language into real-world implications, brokers elevate their role from vendor manager to strategic advisor. 

Moving Beyond the Contract

PBM contracts are necessary. They are not sufficient.

Employers who manage pharmacy effectively recognize that true transparency comes from:

• Ongoing review, not just annual negotiation
• Understanding incentives, not just pricing
• Asking how decisions are made, not just what they cost

When contracts are paired with intentional oversight, pharmacy becomes a manageable risk instead of a recurring surprise.

The Takeaway

PBM contracts tell part of the story. The rest lives in incentives, discretion, and operational decisions that rarely fit neatly into contract language.

For employers and brokers willing to look beyond the fine print, that understanding creates opportunity. Opportunity to reduce blind spots, strengthen governance, and make more informed decisions about one of the most complex parts of the health plan.